{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-091874","form_type":"8-K","ticker":null,"cik":"0001584751","company_name":"Talis Biomedical Corp","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.646373+00:00","generated_at":"2026-05-31T12:16:26.312059+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Talis Biomedical adds restructuring directors, authorizes potential Ch. 11 filing","bullets":["Director Heinrich Dreismann resigned effective Aug 1, 2024; Patricia Ferrari and John T. Young Jr. elected.","New Special Restructuring Committee (Ferrari, Young) authorized to settle securities class action, file Ch. 11, and investigate officer/director claims.","Ferrari and Young each receive $35,000/month guaranteed for at least 6 months or until bankruptcy plan confirmed.","Young receives $10,000/yr as Audit Committee chair; both have deep bankruptcy and liquidation experience."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-091874","json":"https://secwatch.observer/filing/0000950170-24-091874.json","markdown":"https://secwatch.observer/filing/0000950170-24-091874.md","text":"https://secwatch.observer/filing/0000950170-24-091874.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1584751/000095017024091874/0000950170-24-091874-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1584751/000095017024091874/tlis-20240731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:16:26.312059+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"27e3ce5c6e","claim":"Heinrich Dreismann resigned as Director at Talis Biomedical Corp.","evidence_excerpt":"Accepting the voluntary resignation of Heinrich Dreismann from the Board effective August 1, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1584751/000095017024091874/0000950170-24-091874-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"555a2c8ffd","claim":"John T. Young, Jr. was elected as Director at Talis Biomedical Corp.","evidence_excerpt":"Electing each of Patricia Ferrari and John T. Young, Jr. to the Board effective July 31, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1584751/000095017024091874/0000950170-24-091874-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"58f7c30309","claim":"Patricia Ferrari was elected as Director at Talis Biomedical Corp.","evidence_excerpt":"Electing each of Patricia Ferrari and John T. Young, Jr. to the Board effective July 31, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1584751/000095017024091874/0000950170-24-091874-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}